Denali Therapeutics stock (US24823R1077): biotech name steadies after strong May rally on Nasdaq

Denali Therapeutics shares started the new week on the Nasdaq in the United States trading close to recent levels around USD 20.95 after a notable move higher in late May, leaving the neuro-focused biotech stock up strongly over the past seven days.

According to the Nasdaq exchange, Denali Therapeutics, which trades under the ticker DNLI, closed at about USD 20.95 on 05/29/2026, representing a gain of roughly 3.7% over the previous 24 hours and leaving the stock higher by more than 13% over the past week as reported by German financial portal wallstreet-online as of 05/29/2026.

The stock is listed in the United States on Nasdaq and is part of the American biotechnology segment, with recent data from wallstreet-online on 05/29/2026 indicating that Denali Therapeutics is still trading about 16% below its 52-week high while standing roughly 60% above its 52-week low, underscoring how the shares have recovered from earlier weakness but remain well short of prior peaks.

The same data set from 05/29/2026 shows that Denali Therapeutics has delivered a one-year performance of more than 50%, suggesting that the stock has outperformed many broader benchmarks over this period even as short-term moves have been volatile.

Market capitalization figures compiled by CompaniesMarketCap and based on Nasdaq data indicate that Denali Therapeutics had an equity value of about USD 3.07 billion as of 05/14/2026, positioning the company in the mid-cap range among global listed biotech names.

For investors following the stock from Germany, wallstreet-online quotes also show a Tradegate price in euros, with a realtime level of about EUR 18.04 on 05/29/2026, highlighting the availability of Denali Therapeutics shares on German trading venues alongside the primary United States listing.

While there has been no new earnings release or major corporate announcement in the last few days, the sustained price gains into the end of May and the stock’s improving one-year performance keep Denali Therapeutics in focus as the market tracks sentiment around clinical and pipeline developments in the broader neurodegenerative disease space.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

Denali Therapeutics: core business model

Denali Therapeutics focuses on discovering and developing therapeutic candidates that target neurodegenerative and certain lysosomal diseases, with future revenue potential tied largely to the successful clinical development, regulatory approval and commercialization of its central nervous system pipeline, often in collaboration with larger pharmaceutical partners.

What banks and research houses say about Denali Therapeutics

Analyst coverage of Denali Therapeutics remains active, with data compiled by wallstreet-online as of 05/29/2026 indicating that a clear majority of analysts tracked by the portal rate the shares in the top recommendation brackets, although individual price targets and report dates can vary across institutions.

According to this snapshot, about 79% of the analysts surveyed assign a Strongbuy rating to Denali Therapeutics while roughly 22% mark the stock as Buy, resulting in an aggregated rating score of 4.79 out of 5 on the wallstreet-online scale as of 05/29/2026, which underscores a broadly positive stance from covering research houses without providing a uniform view on valuation or timing.

Conclusion

Denali Therapeutics enters June with its Nasdaq-listed shares holding near USD 21 after a sharp move higher in late May, supported by a substantially improved one-year performance profile and a market capitalization in the low single-digit billion dollar range. The aggregated analyst backdrop presented by wallstreet-online as of 05/29/2026 shows a predominantly positive rating mix, which many investors view alongside the company’s clinical progress and sector sentiment when assessing the stock’s risk-reward profile. How future trial milestones, regulatory interactions and broader biotech market moves evolve will likely remain key for the trajectory of Denali Therapeutics shares in the United States and on secondary trading venues such as Tradegate in Germany.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.